News
ORXOF
0.082
NaN%
--
Orexo Presents OX640 Data on Epinephrine Levels and Stability
TipRanks · 11/13 09:16
Orexo, SVF Vaccines to Explore Powder-Based LNP-mRNA Vaccine Formulation
TipRanks · 11/11 08:00
Orexo Announces Two OX640 Data Presentations at ACAAI 2026
TipRanks · 11/10 08:40
Orexo Shareholders Approve Rights Issue and Financing Measures
TipRanks · 11/06 09:32
Orexo Sets Terms for SEK 253 Million Rights Issue
TipRanks · 11/02 21:49
Orexo Wins FDA Review of High‑Dose Naloxone Nasal Powder IZIPRY
TipRanks · 10/29 10:38
Orexo AB Earnings Call: Pipeline Progress Amid Strain
TipRanks · 10/26 00:10
Orexo Deepens R&D-Driven Transformation Amid Losses and Capital Raise
TipRanks · 10/22 05:35
Orexo to Present Q3 2026 Interim Results in Live Investor Call
TipRanks · 10/16 08:34
Orexo’s AmorphOX® tech shows promising oral semaglutide bioavailability
TipRanks · 10/14 06:32
Orexo launches 250 MSEK rights issue to fund pipeline and strengthen finances
TipRanks · 10/06 06:36
Orexo convenes EGM to approve rights issue and capital authorizations
TipRanks · 10/06 06:33
Orexo Resubmits High-Dose Opioid Overdose Rescue Drug IZIPRY for FDA Review
TipRanks · 09/29 14:03
Orexo Wins FDA Green Light to Advance Needle‑Free Anaphylaxis Treatment OX640
TipRanks · 09/14 06:33
Orexo Wins BARDA Funding Boost to Extend OX390 Overdose Rescue Development
TipRanks · 09/10 06:34
Orexo CFO Fredrik Järrsten to Step Down as Company Streamlines Operations
TipRanks · 09/01 19:32
Orexo Moves to Settle U.S. DOJ Probe With Non‑Prosecution Deal
TipRanks · 08/31 06:34
Orexo AB Earnings Call: Science Progress, Cash Strain
TipRanks · 07/17 00:07
Orexo Advances Nasal Rescue Pipeline as Losses Deepen in Q2 2026
TipRanks · 07/16 05:38
Orexo strengthens partnership strategy with new business development chief
TipRanks · 06/09 06:43
More
Webull provides a variety of real-time ORXOF stock news. You can receive the latest news about Orexo Ab through multiple platforms. This information may help you make smarter investment decisions.
About ORXOF
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.